top of page

After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection

  • blonca9
  • Apr 1
  • 1 min read

He describes why a 'one-size-fits-all' approach has caused numerous ophthalmology trials to fail in the past, and why Character believes a precision medicine approach is overdue.




Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page